News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories News OKSPOT Unveils Privacy-Focused Crypto Exchange for Global Traders With No-KYC Registration and Monero Support News Mambu and Mastercard expand cross-border payment capabilities for banks across APAC News Indonesia’s ITS Celebrates 66th Anniversary and Officially Closes KSTI 2026 News Shaping the Future Together: Voices from Around the World at the III International Symposium ‘Creating the Future’ in Russia News The UAE’s AI Adoption Is a World Record. Paying for It Is Another Story News Indonesia seeks to preserve historic railway assets as part of global heritage